Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies

Med Oncol. 2023 May 10;40(6):173. doi: 10.1007/s12032-023-02018-5.

Abstract

Dasatinib is the 2nd generation TKI (Tyrosine Kinase Inhibitor) having the potential to treat numerous forms of leukemic and cancer patients and it is 300 times more potent than imatinib. Cancer is the major cause of death globally and need to enumerate novel strategies to coping with it. Various novel therapeutics introduced into the market for ease in treating various forms of cancer. We reviewed and evaluated all the related aspects of dasatinib, which can enhance the knowledge about dasatinib therapeutics methodology, pharmacodynamic and pharmacokinetics, side effects, advantages, disadvantages, various kinds of interactions and its novel formulations as well.

Keywords: Bioavailability; Cancer; Dasatinib; Formulations; Side effects; Solubility; Tyrosine kinase inhibitor.

Publication types

  • Review

MeSH terms

  • Dasatinib / pharmacology
  • Dasatinib / therapeutic use
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Protein Kinase Inhibitors / adverse effects
  • Tyrosine Kinase Inhibitors*

Substances

  • Dasatinib
  • Tyrosine Kinase Inhibitors
  • Protein Kinase Inhibitors
  • Imatinib Mesylate